Taro Pharmaceutical Industries Ltd. TARO

$ 42.97 0.0%

Annual report 2022
added 07-25-2022

Taro Pharmaceutical Industries Ltd. Balance Sheet 2011-2024 | TARO

Annual Balance Sheet Taro Pharmaceutical Industries Ltd.

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-	-513 M	-567 M	-577 M	-600 M	-577 M	-476 M	-192 M	-209 M	-199 M	-105 M
Long Term Debt	-	-	-	-	-	-	-	4.98 M	5.9 M	17.3 M	27.9 M	27.6 M
Long Term Debt Current	2.2 M	1.69 M	-	-	-	-	-	912 K	12 M	11.3 M	11 M	17.1 M
Total Non Current Liabilities	32.8 M	35.1 M	14.7 M	13 M	12.3 M	12.4 M	11.4 M	16 M	15.6 M	27.8 M	38.5 M	38.2 M
Total Current Liabilities	432 M	676 M	223 M	217 M	216 M	210 M	245 M	310 M	253 M	193 M	199 M	190 M
Total Liabilities	465 M	711 M	237 M	230 M	228 M	222 M	257 M	326 M	269 M	220 M	237 M	229 M
Deferred Revenue	5.79 M	7.58 M	-	111 M	87.3 M	2.11 M	2.23 M	4.15 M	4.9 M	5.49 M	6.45 M	12.3 M
Retained Earnings	2.39 B	2.34 B	2.73 B	2.48 B	2.66 B	2.45 B	1.99 B	1.45 B	970 M	609 M	343 M	296 M
Total Assets	2.18 B	2.41 B	2.34 B	2.14 B	2.43 B	2.29 B	2.19 B	1.74 B	1.28 B	1.11 B	856 M	796 M
Cash and Cash Equivalents	251 M	605 M	513 M	567 M	577 M	600 M	577 M	482 M	210 M	237 M	238 M	150 M
Book Value	1.71 B	1.7 B	2.1 B	1.91 B	2.21 B	2.07 B	1.93 B	1.41 B	1.02 B	886 M	619 M	567 M
Total Shareholders Equity	1.71 B	1.7 B	2.11 B	1.91 B	2.21 B	2.07 B	1.93 B	1.41 B	1.02 B	886 M	619 M	567 M

All numbers in USD currency

Quarterly Balance Sheet Taro Pharmaceutical Industries Ltd.

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.98 M	-	-	-	5.89 M	-	-	-	17.3 M	-	-	-	27.9 M	27.6 M	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	35.1 M	-	-	-	8.76 M	-	-	-	7.38 M	-	-	-	7.06 M	-	-	-	6.11 M	-	-	-	5.43 M	-	-	-	10.4 M	-	-	-	10.5 M	-	-	-	23.1 M	-	-	-	34.6 M	34.4 M	-	-	-
Total Liabilities	-	-	-	-	-	-	-	711 M	-	-	-	231 M	-	-	-	224 M	-	-	-	223 M	-	-	-	216 M	-	-	-	251 M	-	-	-	320 M	-	-	-	264 M	-	-	-	216 M	-	-	-	233 M	225 M	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	7.58 M	-	-	-	237 K	-	-	-	9.44 M	-	-	-	223 K	-	-	-	167 K	-	-	-	799 K	-	-	-	79 K	-	-	-	19.9 M	-	-	-	351 K	-	-	-	-	-	-	-	-
Retained Earnings	-	-	-	-	-	-	-	2.34 B	-	-	-	2.73 B	-	-	-	2.48 B	-	-	-	2.66 B	-	-	-	2.45 B	-	-	-	1.99 B	-	-	-	1.45 B	-	-	-	970 M	-	-	-	609 M	-	-	-	343 M	296 M	-	-	-
Total Assets	-	-	-	-	-	-	-	2.41 B	-	-	-	2.34 B	-	-	-	2.14 B	-	-	-	2.43 B	-	-	-	2.29 B	-	-	-	2.19 B	-	-	-	1.74 B	-	-	-	1.28 B	-	-	-	1.11 B	-	-	-	856 M	796 M	-	-	-
Cash and Cash Equivalents	-	-	-	-	-	-	-	605 M	-	-	-	513 M	-	-	-	567 M	-	-	-	577 M	-	-	-	600 M	-	-	-	577 M	-	-	-	482 M	-	-	-	210 M	-	-	-	237 M	-	-	-	238 M	150 M	-	-	78.9 M
Book Value	-	-	-	-	-	-	-	1.7 B	-	-	-	2.11 B	-	-	-	1.91 B	-	-	-	2.21 B	-	-	-	2.07 B	-	-	-	1.94 B	-	-	-	1.42 B	-	-	-	1.02 B	-	-	-	891 M	-	-	-	623 M	571 M	-	-	-
Total Shareholders Equity	-	-	-	-	-	-	-	1.7 B	-	-	-	2.1 B	-	-	-	1.91 B	-	-	-	2.21 B	-	-	-	2.07 B	-	-	-	1.93 B	-	-	-	1.41 B	-	-	-	1.02 B	-	-	-	886 M	-	-	-	619 M	567 M	-	-	-

All numbers in USD currency